Dianthus Therapeutics, Inc.

Dianthus Therapeutics is a specific clinical-stage biotech whose specific pipeline has driven a specific 381% twelve-month run. The stock is at 92% of its 52-week range on the specific catalyst-anticipation setup.

Where both sides land:

• The tape confirms specific institutional flow: sitting 7.6% above the 50-day and 52% above the 200-day at 92% of the 52-week range with volume roughly at average — the specific pattern of a stock riding data-driven momentum.
• The economics are pre-revenue by design: 94% gross margin at -143% operating margin with -3% FCF yield and -16% ROIC — meaning DNTH is a pure claim on the specific pipeline milestones arriving.
• The valuation is extreme: 3,165x TTM sales because revenue is trivial — meaning the equity is priced entirely on the specific pipeline-data trajectory.
• The check is the specific position at the top: at 92% of range, any specific data disappointment or safety-signal disclosure produces violent unwind.

Aug 6 earnings is the trigger. A number confirming specific pipeline milestone timing plus cash-runway commentary extends the leg materially; a specific timeline slippage or safety-signal disclosure is the specific setup for violent give-back.